A Phase II Clinical Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer

Trial Profile

A Phase II Clinical Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs Amcasertib (Primary)
  • Indications Cholangiocarcinoma; Liver cancer
  • Focus Therapeutic Use
  • Sponsors Boston Biomedical
  • Most Recent Events

    • 10 Nov 2017 Status changed from recruiting to active, no longer recruiting.
    • 11 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
    • 25 Mar 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top